Kiromic BioPharma, Inc.
KRBPQ
$0.0615
-$0.083-57.44%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.15% | -15.65% | -3.52% | -19.03% | -44.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.30% | 18.93% | 47.99% | 7.03% | -23.18% |
| Operating Income | -7.30% | -18.93% | -47.99% | -7.03% | 23.18% |
| Income Before Tax | -38.37% | -77.28% | -0.90% | -16.00% | 33.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.37% | -77.28% | -0.90% | -16.00% | 33.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.37% | -77.28% | -0.90% | -16.00% | 33.63% |
| EBIT | -7.30% | -18.93% | -47.99% | -7.03% | 23.18% |
| EBITDA | -7.87% | -21.24% | -54.81% | -7.94% | 25.20% |
| EPS Basic | 314.72% | -43.03% | 20.70% | 11.50% | 126.88% |
| Normalized Basic EPS | -13.72% | -35.17% | 29.37% | 22.39% | 68.26% |
| EPS Diluted | 314.72% | -43.03% | 20.70% | 11.50% | 126.88% |
| Normalized Diluted EPS | -13.72% | -35.17% | 29.37% | 22.39% | 68.26% |
| Average Basic Shares Outstanding | 21.67% | 29.91% | 42.85% | 49.46% | 109.12% |
| Average Diluted Shares Outstanding | 21.67% | 29.91% | 42.85% | 49.46% | 109.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |